Amgen Presents at MEDCAC Meeting on ESAs in Chronic Kidney Disease

On Wednesday, March 24, 2010, Amgen presented evidence supporting the use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) at the Centers for Medicare and Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) Meeting.